Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Paratesticular Sarcoma: Typical Presentation, Imaging Features, and Clinical Challenges.

Ap Dafydd D, Messiou C, Thway K, Strauss DC, Nicol DL, Moskovic E.

Urology. 2017 Feb;100:163-168. doi: 10.1016/j.urology.2016.09.005. Epub 2016 Sep 14.

PMID:
27639792
2.

Hypermethylation of the 5' CpG island of the gene encoding the serine protease Testisin promotes its loss in testicular tumorigenesis.

Manton KJ, Douglas ML, Netzel-Arnett S, Fitzpatrick DR, Nicol DL, Boyd AW, Clements JA, Antalis TM.

Br J Cancer. 2015 Dec 1;113(11):1640. doi: 10.1038/bjc.2015.384. No abstract available.

3.

Patients Who Receive Androgen Deprivation Therapy Risk Adverse Cognitive Changes.

Gardiner RA, Yaxley J, Pakenham KI, Green H, Mactaggart P, Watson R, Swanson C, Nicol DL.

J Clin Oncol. 2015 Dec 20;33(36):4314-5. doi: 10.1200/JCO.2015.63.5698. Epub 2015 Oct 26. No abstract available.

PMID:
26503208
4.

Clean intermittent self-catheterization does not appear to be effective in the prevention of urethral stricture recurrence.

Greenwell TJ, Castle C, Nicol DL.

Scand J Urol. 2016;50(1):71-3. doi: 10.3109/21681805.2015.1086888. Epub 2015 Oct 1.

PMID:
26428415
5.

Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution.

Kovac M, Navas C, Horswell S, Salm M, Bardella C, Rowan A, Stares M, Castro-Giner F, Fisher R, de Bruin EC, Kovacova M, Gorman M, Makino S, Williams J, Jaeger E, Jones A, Howarth K, Larkin J, Pickering L, Gore M, Nicol DL, Hazell S, Stamp G, O'Brien T, Challacombe B, Matthews N, Phillimore B, Begum S, Rabinowitz A, Varela I, Chandra A, Horsfield C, Polson A, Tran M, Bhatt R, Terracciano L, Eppenberger-Castori S, Protheroe A, Maher E, El Bahrawy M, Fleming S, Ratcliffe P, Heinimann K, Swanton C, Tomlinson I.

Nat Commun. 2015 Mar 19;6:6336. doi: 10.1038/ncomms7336.

6.

Multidisciplinary urological engagement in translational renal cancer research.

Stewart GD, Harrison DJ, Swanton C, Lewis R, Bliss J, Larkin J, Nicol DL; A-PREDICT TMG.

BJU Int. 2014 Oct;114(4):474-5. doi: 10.1111/bju.12697. Epub 2014 Jul 28. No abstract available.

7.

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing.

Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, Fisher R, McGranahan N, Matthews N, Santos CR, Martinez P, Phillimore B, Begum S, Rabinowitz A, Spencer-Dene B, Gulati S, Bates PA, Stamp G, Pickering L, Gore M, Nicol DL, Hazell S, Futreal PA, Stewart A, Swanton C.

Nat Genet. 2014 Mar;46(3):225-233. doi: 10.1038/ng.2891. Epub 2014 Feb 2.

8.

PITX2 and non-canonical Wnt pathway interaction in metastatic prostate cancer.

Vela I, Morrissey C, Zhang X, Chen S, Corey E, Strutton GM, Nelson CC, Nicol DL, Clements JA, Gardiner EM.

Clin Exp Metastasis. 2014 Feb;31(2):199-211. doi: 10.1007/s10585-013-9620-7. Epub 2013 Oct 26.

PMID:
24162257
9.

Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas.

Gerlinger M, Quezada SA, Peggs KS, Furness AJ, Fisher R, Marafioti T, Shende VH, McGranahan N, Rowan AJ, Hazell S, Hamm D, Robins HS, Pickering L, Gore M, Nicol DL, Larkin J, Swanton C.

J Pathol. 2013 Dec;231(4):424-32. doi: 10.1002/path.4284.

10.

Incidental renal cell carcinoma identified during laparoscopic live-related donor nephrectomy.

Bycroft JA, Benaragama KS, Green A, Lindsey B, Nicol DL.

JRSM Short Rep. 2010 Sep 20;1(4):32. doi: 10.1258/shorts.2010.010039. No abstract available.

11.

Open and laparoscopic donor nephrectomy: activity and outcomes from all Australasian transplant centers.

Brook NR, Gibbons N, Nicol DL, McDonald SP.

Transplantation. 2010 Jun 27;89(12):1482-8. doi: 10.1097/TP.0b013e3181dd35a0.

PMID:
20418804
12.

Expression of PSA-RP2, an alternatively spliced variant from the PSA gene, is increased in prostate cancer tissues but the protein is not secreted from prostate cancer cells.

Whitbread AK, Veveris-Lowe TL, Dong Y, Tan OL, Gardiner R, Samaratunga HM, Nicol DL, Clements JA.

Biol Chem. 2010 Apr;391(4):461-6. doi: 10.1515/BC.2010.043.

PMID:
20180647
13.

Silibinin--a promising new treatment for cancer.

Cheung CW, Gibbons N, Johnson DW, Nicol DL.

Anticancer Agents Med Chem. 2010 Mar;10(3):186-95. Review.

PMID:
20015009
14.

Outcomes of transplants from patients with small renal tumours, live unrelated donors and dialysis wait-listed patients.

Brook NR, Gibbons N, Johnson DW, Nicol DL.

Transpl Int. 2010 May 1;23(5):476-83. doi: 10.1111/j.1432-2277.2009.01002.x. Epub 2009 Dec 8.

15.

Predicting risk of nonmelanoma skin cancer and premalignant skin lesions in renal transplant recipients.

Urwin HR, Jones PW, Harden PN, Ramsay HM, Hawley CM, Nicol DL, Fryer AA.

Transplantation. 2009 Jun 15;87(11):1667-71. doi: 10.1097/TP.0b013e3181a5ce2e.

PMID:
19502958
16.

Intravenous versus oral iron supplementation for correction of post-transplant anaemia in renal transplant patients.

Mudge DW, Tan KS, Miles R, Johnson DW, Campbell SB, Hawley CM, Isbel NM, Van Eps CL, Nicol DL.

BMC Nephrol. 2009 Jun 6;10:14. doi: 10.1186/1471-2369-10-14.

17.

Change in live donor characteristics over the last 25 years: a single centre experience.

Kaisar MO, Nicol DL, Hawley CM, Mudge DW, Johnson DW, Preston JM, Wall DR, Griffin AD, Campbell SB, Isbel NM.

Nephrology (Carlton). 2008 Oct;13(7):646-50. doi: 10.1111/j.1440-1797.2008.01039.x.

PMID:
19161367
18.

Kidneys from patients with small renal tumours: a novel source of kidneys for transplantation.

Nicol DL, Preston JM, Wall DR, Griffin AD, Campbell SB, Isbel NM, Hawley CM, Johnson DW.

BJU Int. 2008 Jul;102(2):188-92; discussion 192-3. doi: 10.1111/j.1464-410X.2008.07562.x. Epub 2008 Jul 1.

19.

Therapeutic value of orally administered silibinin in renal cell carcinoma: manipulation of insulin-like growth factor binding protein-3 levels.

Cheung CW, Taylor PJ, Kirkpatrick CM, Vesey DA, Gobe GC, Winterford C, Nicol DL, Johnson DW.

BJU Int. 2007 Aug;100(2):438-44.

20.

Epithelial-mesenchymal transition in prostate cancer and the potential role of kallikrein serine proteases.

Lawrence MG, Veveris-Lowe TL, Whitbread AK, Nicol DL, Clements JA.

Cells Tissues Organs. 2007;185(1-3):111-5. Review.

PMID:
17587816
21.
22.

Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer.

Gao J, Collard RL, Bui L, Herington AC, Nicol DL, Clements JA.

Prostate. 2007 Mar 1;67(4):348-60.

PMID:
17221837
23.

Bone and prostate cancer cell interactions in metastatic prostate cancer.

Vela I, Gregory L, Gardiner EM, Clements JA, Nicol DL.

BJU Int. 2007 Apr;99(4):735-42. Epub 2006 Dec 13. Review.

24.

A randomized controlled trial of coiled versus straight swan-neck Tenckhoff catheters in peritoneal dialysis patients.

Johnson DW, Wong J, Wiggins KJ, Kirwan R, Griffin A, Preston J, Wall D, Campbell SB, Isbel NM, Mudge DW, Hawley CM, Nicol DL.

Am J Kidney Dis. 2006 Nov;48(5):812-21.

PMID:
17060001
25.
26.

Side-effects of treatments for locally advanced prostate cancer.

Gardiner RF, Nicol DL, Green HJ, Pakenham KI.

BJU Int. 2006 Jul;98(1):229-30. No abstract available.

27.

Laparoscopic vs open living donor nephrectomy: a contemporary series from one centre.

Power RE, Preston JM, Griffin A, Martin I, Wall DR, Nicol DL.

BJU Int. 2006 Jul;98(1):133-6.

28.

The role of kallikrein-related peptidases in prostate cancer: potential involvement in an epithelial to mesenchymal transition.

Whitbread AK, Veveris-Lowe TL, Lawrence MG, Nicol DL, Clements JA.

Biol Chem. 2006 Jun;387(6):707-14. Review.

PMID:
16800731
29.

Deceased donor renal transplantation--does side matter?

Johnson DW, Mudge DW, Kaisar MO, Campbell SB, Hawley CM, Isbel NM, Wall D, Griffin A, Preston J, Nicol DL.

Nephrol Dial Transplant. 2006 Sep;21(9):2583-8. Epub 2006 May 30.

PMID:
16735388
30.

Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients.

Armstrong KA, Campbell SB, Hawley CM, Nicol DL, Johnson DW, Isbel NM.

Am J Transplant. 2005 Nov;5(11):2710-8.

31.

Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.

Veveris-Lowe TL, Lawrence MG, Collard RL, Bui L, Herington AC, Nicol DL, Clements JA.

Endocr Relat Cancer. 2005 Sep;12(3):631-43.

PMID:
16172196
32.

Testicular germ cell tumors exhibit evidence of hormone dependence.

Douglas ML, Richardson MM, Nicol DL.

Int J Cancer. 2006 Jan 1;118(1):98-102.

33.

Hypermethylation of the 5' CpG island of the gene encoding the serine protease Testisin promotes its loss in testicular tumorigenesis.

Manton KJ, Douglas ML, Netzel-Arnett S, Fitzpatrick DR, Nicol DL, Boyd AW, Clements JA, Antalis TM.

Br J Cancer. 2005 Feb 28;92(4):760-9. Erratum in: Br J Cancer. 2015 Dec 1;113(11):1640.

34.

Obliterative bronchiolitis or opportunistic infection? A diagnostic challenge in a renal transplant patient.

Mudge DW, Johnson DW, Isbel NM, Campbell SB, Nicol DL, Hawley CM.

Nephrol Dial Transplant. 2005 Jan;20(1):246-7. No abstract available.

PMID:
15632365
35.

Polymorphisms in glutathione S-transferases and non-melanoma skin cancer risk in Australian renal transplant recipients.

Fryer AA, Ramsay HM, Lovatt TJ, Jones PW, Hawley CM, Nicol DL, Strange RC, Harden PN.

Carcinogenesis. 2005 Jan;26(1):185-91. Epub 2004 Sep 30.

PMID:
15459020
36.

Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.

Gardiner RA, Nicol DL, Green HJ, Yaxley J, Watson R, Mactaggart P, Headley BC, Swanson C, Pakenham KI.

J Urol. 2004 Aug;172(2):774; author reply 774-5. No abstract available.

PMID:
15247782
37.

Repeat urethrotomy and dilation for the treatment of urethral stricture are neither clinically effective nor cost-effective.

Greenwell TJ, Castle C, Andrich DE, MacDonald JT, Nicol DL, Mundy AR.

J Urol. 2004 Jul;172(1):275-7.

PMID:
15201793
38.

Papillary urothelial neoplasm of low malignant potential: reliability of diagnosis and outcome.

Campbell PA, Conrad RJ, Campbell CM, Nicol DL, MacTaggart P.

BJU Int. 2004 Jun;93(9):1228-31.

39.

Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial.

Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, Swanson CE, Watson RB, Gardiner RA.

BJU Int. 2004 May;93(7):975-9.

40.

Endothelin axis expression is markedly different in the two main subtypes of renal cell carcinoma.

Douglas ML, Richardson MM, Nicol DL.

Cancer. 2004 May 15;100(10):2118-24.

41.
42.

The effect of oral iron admiinistration on mycophenolate mofetil absorption in renal transplant recipients: a randomized, controlled trial.

Mudge DW, Atcheson B, Taylor PJ, Sturtevant JM, Hawley CM, Campbell SB, Isbel NM, Nicol DL, Pillans PI, Johnson DW.

Transplantation. 2004 Jan 27;77(2):206-9.

PMID:
14742982
43.

Frequency and severity of acute rejection in live- versus cadaveric-donor renal transplants.

Campbell SB, Hothersall E, Preston J, Brown AM, Hawley CM, Wall D, Griffin AD, Isbel NM, Nicol DL, Johnson DW.

Transplantation. 2003 Nov 27;76(10):1452-7.

PMID:
14657685
44.

Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia.

Ramsay HM, Fryer AA, Hawley CM, Smith AG, Nicol DL, Harden PN.

J Am Acad Dermatol. 2003 Sep;49(3):397-406.

PMID:
12963901
45.

Use of mycophenolate mofetil in immunosuppressive protocols in elderly renal transplant recipients.

Johnson DW, Nicol DL, Preston JM, Brown AM, Hawley CM, Campbell SB, Wall D, Griffin AD, Isbel NM.

Transplantation. 2003 Aug 15;76(3):619. No abstract available.

PMID:
12923455
46.

A single-centre experience of post-renal transplant lymphoproliferative disorder.

Herzig KA, Juffs HG, Norris D, Brown AM, Gill D, Hawley CM, Cobcroft R, Petrie JB, Marlton P, Thomson D, Campbell SB, Nicol DL, Johnson DW.

Transpl Int. 2003 Jul;16(7):529-36. Epub 2003 May 7.

PMID:
12734646
47.

Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: a prospective study in Queensland, Australia.

Carroll RP, Ramsay HM, Fryer AA, Hawley CM, Nicol DL, Harden PN.

Am J Kidney Dis. 2003 Mar;41(3):676-83.

PMID:
12612993
48.

The role of angiogenesis in prostate development and the pathogenesis of prostate cancer.

Hrouda D, Nicol DL, Gardiner RA.

Urol Res. 2003 Feb;30(6):347-55. Epub 2002 Nov 21. Review.

PMID:
12599013
49.

Durable and high rates of remission following chemotherapy in posttransplantation lymphoproliferative disorders after renal transplantation.

Gill D, Juffs HG, Herzig KA, Brown AM, Hawley CM, Cobcroft RG, Petrie JJ, Marlton P, Kennedy G, Thomson DB, Campbell SB, Nicol DL, Norris D, Johnson DW.

Transplant Proc. 2003 Feb;35(1):256-7. Review. No abstract available.

PMID:
12591388
50.

The effect of obesity on renal transplant outcomes.

Johnson DW, Isbel NM, Brown AM, Kay TD, Franzen K, Hawley CM, Campbell SB, Wall D, Griffin A, Nicol DL.

Transplantation. 2002 Sep 15;74(5):675-81.

PMID:
12352885

Supplemental Content

Loading ...
Support Center